ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

[News]

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

More... (http://www.news-medical.net/news/20111116/ZIOPHARM-announces-new-preclinical-data-from-two-darinaparsin-studies-on-solid-tumors.aspx)